Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA)

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 1061-1067

  Vogelsang, G B ^a,c   Wolff, D ^a   Altomonte, V ^a   Farmer, E ^b,d   Morison, W L ^a   Corio, R ^a   Horn, T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic GVHD; Complications of BMT; PUVA

Indexed keywords

PHOTOSENSITIZING AGENT; PSORALEN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; ORAL DRUG ADMINISTRATION; PHOTOTOXICITY; PRIORITY JOURNAL; PUVA; SCHOOL CHILD; TREATMENT OUTCOME; ULTRAVIOLET IRRADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; MIDDLE AGED; PUVA THERAPY;

EID: 0030018882     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hymes SR, Morison WL, Farmer ER et al. Methoxsalen and ultraviolet. A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985; 12: 30-37.
2. Atkinson K, Weller P, Ryman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1: 227-236.
3. Volc-Platzer B, Hönigsmann H, Hinterberger W, Wolff K. Photochemotherapy improves chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 1990; 23: 220-228.
4. Eppinger T, Ehninger G, Steinert M et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807-811.
5. Jampel RM, Farmer ER, Vogelsang GB et al. PUVA therapy for chronic cutaneous graft-versus-host disease. Arch Dermatol 1991; 127: 1673-1678.
6. Kapoor N, Pelligrini AE, Copelan EA et al. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients. Semin Hematol 1992; 29: 108-112.
7. Reinhauer S, Lehmann P, Plewig G et al. Photochemotherapie (PUVA) der Akuten Graft-versus-Host-Erkrankung. Hautartz 1993; 44: 708-712.
8. Aubin F, Brion A, Deconick E et al. Phototherapy in the treatment of cutaneous graft-versus-host disease. Transplantation 1995; 59: 151-155.
9. Wingaard JR, Piantadosi S, Vogelsang GB et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74: 1428-1435.
10. Hood AF, Farmer ER. Graft-versus-host disease. Dermatology in General Medicine, 4th edn. McGraw-Hill: New York, 1993, pp 1510-1519.
11. Morison WL. Phototherapy and Photochemotherapy of Skin Disease, 2nd edn. Raven Press: New York, 1991.
12. Glazier A, Morison WL, Bucana C et al. Suppression of epidermal graft-versus-host-disease with ultraviolet radiation. Transplantation 1984; 37: 211-212.
13. Bagot M, Heslan M, Roujeau JC et al. Human epidermal cells are more potent than peripheral blood mononuclear cells for the detection of weak allogeneic or viral specific primary responses in vitro. Cell Immunol 1985; 94: 215-224.
14. Steinmann RM. The dentritic cell system and its role in immunogenicity. Ann Rev Immunol 1991; 9: 271-296.
15. Stingl LA, Sauder DN, Iijima M et al. Mechanism of UV-B-induced impairment of the antigen-presenting capacity of murine epidermal cells. J Immunol 1983; 130: 1586-1591.
16. Simon JC, Tigelaar RE, Bergstresser PR et al. Ultraviolet B radiation converts langerhans cells from immunogenic to tolerogenic antigen-presenting cells. J Immunol 1991; 146: 485-491.
17. Ashworth J, Kahan MC, Breathnach SM. PUVA therapy decreases HLA-DR+ CD1a+ Langerhans cells and epidermal cell antigen-presenting capacity in human skin, but flow cytometrically-sorted residual HLA-DR+ CD1a+ Langerhans-cells exhibit normal alloantigen-presenting function. Br J Dermatol 1989; 120: 329-339.
18. Gruner S, Hofmann T, Meffert H, Sönnichsen N. Studies on the effect of a high dose UVA-1 radiation therapy on surface markers and function of epidermal langerhans cells. Arch Dermatol Res 1993; 285: 283-286.
19. Bergfelt L. UV-related skin conditions and langerhans cell populations in human skin. Acta dermato venereologica 1993; 73: 194-196.
20. Neuner P, Charvat B, Knobler R et al. Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UV-A. Photochem Photobiol 1994; 59: 182-188.
21. Okamoto H, Horio T, Maeda M. Alteration of lymphocyte functions by 8-methoxypsoralen and long-wave ultraviolet radiation. II. The effect of in vivo PUVA on IL-2 production. J Investigat Dermatol 1987; 89: 24-26.
22. Bredberg A, Forsgren A. Effects of in vitro PUVA on human leukocyte function. Br J Dermatol 1984; 111: 159-168.
23. Laskin JD, Mermelstein FH, Heindel ND, Ron Y. Selective inactivation of lymphocytes after psoralen/ultraviolet light (PUVA) treatment without affecting systemic immune responses. J Leukocyte Biol 1993; 54: 138-143.
24. Holler E, Kolb HJ, Hintermeier-Knabe R et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Transplant Proc 1993; 25: 1234-1236.
25. Kock A, Schwarz T, Kirnbauer R et al. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 1990; 172: 1609-1614.
26. Noris DA et al. Ultraviolet radiation can either suppress or induce expression of intercellular adhesion molecule 1 (ICAM-1) on the surface of cultured human keratinocytes. J Investigat Dermatol 1990; 95: 132-138.
27. Enk AH, Katz SI. Identification and induction of keratinocyte-derived IL-10. J Immunol 1992; 149: 92-95.
28. Aubin F, Kripke ML, Ullrich SE. Activation of keratinocytes with psoralen plus UVA radiation induces the release of soluble factors that suppress delayed and contact hypersensitivity. J Investigat Dermatol 1991; 97: 995-1000.
29. Rivas JM, Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated kerinatocytes. J Immunol 1992; 149: 3865-3871.
30. Ullrich SE. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation. J Immunol 1994; 152: 3410-3416.
31. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. J Immunol 1993; 151: 2390-2398.
32. Tukora Y, Yagi J, Edelson RL, Gasparro FP. Inhibitory effect of 8-methoxypsoralen plus ultraviolet-A on interleukin-1 production by murine keratinocytes. Photochem Photobiol 1991; 53: 517-523.
33. Hauser C et al. Interleukin 1 is present in normal human epidermis. J Immunol 1986; 136: 3317-3323.
34. Gahring L, Baltz M, Pepys M et al. Effect of ultraviolet radiation on production of epidermal cell thymocyte-activating factor/IL-1 in vivo and in vitro. Proc Natl Acad Sci USA 1984; 81: 1198-1202.
35. Ansel JC, Luger TA, Lowry D et al. The expression and modulation of IL-1α in murine keratinocytes. J Immunol 1988; 140: 2274-2278.
36. Antin JA, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
37. Durum SK, Schmidt JA, Oppenheim JJ. Interleukin 1: an immunological perspective. Ann Rev Immunol 1985; 3: 263-287.
38. Kerscher M, Volkenandt M, Meuer M et al. Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 1994; 343: 1233.
39. Charley MR, Gilliam JN, Sontheimer RD. Ultraviolet B exposure converts murine lichenoid graft-versus-host skin disease (GvHSD) into sclerotic GVHD. J Investigat Dermatol 1983; 80: 328-329A.
40. Jansen CT, Lehtinen R, Happonen RP et al. Mouth PUVA: new treatment for recalcitrant oral lichen planus. Photodermatology 1987; 4: 165-166.
41. Narwutsch M, Dietz H. Erste Ergebnisse zum Langzeiteffekt des PUVA therapierten Lichen ruber oralis. Dermatologische Monatsschrift 1990; 176: 349-355.
42. Hann SK, Park YK, Sungbin I et al. The effect on liver transaminases of phototoxic drugs used in systemic photochemotherapy. J Am Acad Dermatol 1992; 26: 646-648.
43. Lindelöf B et al. PUVA and cancer: a large-scale epidemiology study. Lancet 1991; 338: 91-93.
44. Abe EA. Cutaneous manifestations of immunosuppression in organ transplant recipients. J Am Acad Dermatol 1989; 21: 167-179.
45. Hartevelt MM, Bavinck JN, Kootte A et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-509.
46. Altman JS, Adler SS. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease. J Am Acad Dermatol 1994; 31: 505-507.